Goodwin Procter: Roche Concludes $4.4 Billion Acquisition of Spark Therapeutics
Goodwin Procter, a law firm, issued the following news release:
Spark Therapeutics (NASDAQ: ONCE) and Roche announced the completion of Roche's acquisition of Spark following the receipt of regulatory approvals from all government authorities required by the merger agreement. The Goodwin team advised Spark on this acquisition.
Roche is acquiring Spark at a price of $114.50 per share in an all-cash transaction. Spark will continue its operations in Philadelphia as an independent compa...